What question did this study set out to answer?

The study aims to evaluate itepekimab as a feasible therapy for managing chronic obstructive pulmonary disease (COPD).

April 10, 2026

Itepekimab for chronic obstructive pulmonary disease therapy

Key Points

The study aims to evaluate itepekimab as a feasible therapy for managing chronic obstructive pulmonary disease (COPD).
Review existing clinical data on itepekimab.
Assess dosing schedules for different disease phases.
Focus on home administration of therapy.
Itepekimab may provide effective management for COPD.
Dosing can be adjusted to every 2 weeks during exacerbations and every 4 weeks when stable.

Abstract

Based on existing clinical data, itepekimab may be a potential therapy for COPD that can be easily administered at home, with dosing tailored to the disease phase (every 2 weeks during exacerbation and every 4 weeks during stable state).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Sabina A Antoniu

Theodor Penisoara

Ștefan Rașcu

Journals

Expert Opinion on Biological Therapy

Actions

Institutions

Carol Davila University of Medicine and Pharmacy

Grigore T. Popa University of Medicine and Pharmacy

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Itepekimab for chronic obstructive pulmonary disease therapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider